Background {#Sec1}
==========

Neuroendocrine neoplasms (NENs) account for 1.25% of all malignancies, with the majority (66%) occurring in the gastrointestinal tract, followed by the bronchopulmonary system (31%). Other less frequent locations include the ovaries, testes, pancreas, and hepatobiliary system. Gallbladder NENs are particularly rare, and 278 cases were registered in the Surveillance, Epidemiology and End Results (SEER) from 1973 to 2005, only representing 0.5% of all NENs and approximately 2% of all gallbladder cancers \[[@CR1],[@CR2]\]. Among all NENs originating in the gallbladder, large-cell neuroendocrine carcinoma (LCNEC) is exceedingly rare, and the first case worldwide was reported in 2000 \[[@CR3]\]. To date, although several case reports of gallbladder LCNEC have been published \[[@CR3]-[@CR16]\] (Table [1](#Tab1){ref-type="table"}), its biological behavior, the appropriate treatment modalities, and the overall patient prognosis remain largely unclear. Herein, we report a rare case of gallbladder LCNEC and present a brief literature review to contribute to the increased understanding of the clinical features of this disease.Table 1**Clinicopathological features of 17 cases of large**-**cell neuroendocrine carcinoma of the gallbladderNumberAuthor** **\[ref.\]Gender/** **agePresentationTumor locationTumor size** **(cm)Liver invasionMetastasisOther componentTreatmentsPrognosis**, **follow**-**up** **(month)**1Papotti *et al*. \[[@CR3]\]M/50UnclearUnclear\<1\--ACChoDFS, 122Papotti *et al*. \[[@CR3]\]M/65UnclearFundus2.5-Liver-ChoDied, 143Jun *et al*. \[[@CR4]\]M/55AP, jaundiceUnclearUnclearUnclearLymph node-Needle biopsy, CheDied, 14Jun *et al*. \[[@CR4]\]F/67APUnclearHuge+Lymph node-Needle biopsy, CheDied, 105Noske and Pahl \[[@CR5]\]F/81AP, jaundiceNeck5+BoneAdenosquamousPalliative surgeryUnknown6Oshiro *et al*. \[[@CR6]\]F/55Back pain, feverBody4.9\--AC, SCNECRadical ChoDFS, 207Shimono *et al*. \[[@CR7]\]F/64APUnclear11.5+\--Che, Rad, extended hepatectomyDFS, 368Iype *et al*. \[[@CR8]\]M/85Anorexia, weight lossFundus1.5-UnclearACCho, CheDied, 219Lin *et al*. \[[@CR9]\]F/65Cushing's syndromeBodyUnclear\-\--(ACTH-producing)Radical Cho, CheDied, 210Sato *et al*. \[[@CR10]\]F/68NegativeFundus3+Lymph nodeACCho, extended hepatectomyDFS, 1211Paniz *et al*. \[[@CR11]\]F/48APFundus3.5+UnclearACCho, extended hepatectomyUnknown12Al-Brahim and Albannai \[[@CR12]\]M/45AP, jaundiceFundus5.7+UnclearACCho, CheUnknown13Okuyam *et al*. \[[@CR13]\]M/64Abdominal fullnessFundus2.5+Lymph node-Biopsy, CheDied, 2214Nakagawa *et al*. \[[@CR14]\]M/56ExophthalmosUnclear9+MultipleACChe, RadDied, 3615Meguro *et al*. \[[@CR15]\]F/54NegativeUnclearUnclear\--ACCho, extrahepatic bile duct resectionDFS, 2416Russo *et al*. \[[@CR16]\]M/59APBody4+Lymph nodeMucinous carcinomaRadical ChoUnknown17Current study, 2014F/63AP, feverBody2.0\--ACRadical ChoDFS, 12AP, abdominal pain; AC, adenocarcinoma; ACTH, adrenocorticotropic hormone; Che, chemotherapy; Cho, cholecystectomy; DFS, disease-free survival; F, female; M, male; Rad, radiotherapy; SCNEC, small-cell neuroendocrine carcinoma.

Case presentation {#Sec2}
=================

A 63-year-old woman came to our emergency room on 14 July 2013, with a history of intermittent right upper quadrant pain that began 3 months prior. Ultrasound indicated no other anomalies, except for a focal thickening of the gallbladder wall. Computed tomography (CT) showed a suspected mass measuring 0.6 × 0.3 cm on the gallbladder plica (Figure [1](#Fig1){ref-type="fig"}a). Because she had a past medical history of cholecystitis, we could not clearly determine whether the mass was a tumor or only thickened mucosa; thus, watchful follow-up was recommended to the patient. On the 29^*th*^ of October 2013, the patient returned to our clinic, and CT scan revealed a 2.0 × 1.8 cm quasi-circular tumor located on the body of the gallbladder in the same location as the mass detected 3.5 months earlier, with significant enhancement in the portal venous phase (Figure [1](#Fig1){ref-type="fig"}b). The results of laboratory tests, including tests for tumor markers and hormonal profiles, were all within normal limits.Figure 1**A fast**-**growing tumor located on the body of the gallbladder. (a)** Computed tomography showed a suspected mass, measuring 0.6 cm, on the gallbladder plica 3.5 months prior. **(b)** At admission 3.5 months later, CT showed a 2.0 × 1.8 cm quasi-circular mass located on the body of gallbladder, with significant enhancement in the portal venous phase.

Laparoscopic cholecystectomy was performed, and an intraoperative frozen pathological section indicated that the lesion was malignant. Immediately thereafter, open radical cholecystectomy with resection of a wedge of the liver and the hepatoduodenal lymph nodes was performed. The gross specimen showed a cauliflower-shaped mass, and microscopically, the tumor consisted of the following two components: moderately differentiated adenocarcinoma and poorly differentiated large-cell neuroendocrine carcinoma (Figure [2](#Fig2){ref-type="fig"}a,b). Immunohistochemically, the neuroendocrine cells exhibited the strong expression of the neuroendocrine markers chromogranin A (Figure [2](#Fig2){ref-type="fig"}c) and synaptophysin (Figure [2](#Fig2){ref-type="fig"}d). In addition, these neuroendocrine cells showed a Ki67 index of over 80%. There was no evidence of serous or liver invasion or lymph node or distant metastasis. Thus, this lesion was assigned a final classification of pT2N0M0 stage II, according to the Union Internationale Contre le Cancer guidelines. The postoperative course of this patient was uneventful, and the carcinoma did not recur during a 12-month follow-up period.Figure 2**Pathologically demonstrated mixed large**-**cell neuroendocrine carcinoma and adenocarcinoma of the gallbladder. (a)** A low-power view (H&E, 100×) demonstrating the combination of a majority of poorly differentiated large cell neuroendocrine carcinoma (LCNEC) cells and a minority of moderately differentiated adenocarcinoma cells (right lower quadrant). **(b)** A high-power view (H&E, 400×) demonstrating that the neuroendocrine carcinoma cells were large in size, polygonal, and contained high numbers of mitotic figures. **(c)** Immunohistochemical staining showing that the LCNEC cells were positive for chromogranin A. **(d)** Immunohistochemical staining showing that the LCNEC cells were positive for synaptophysin.

The present case report is in compliance with the Helsinki Declaration and has been approved by ethics committee of Peking Union Medical College Hospital.

Discussion {#Sec3}
==========

According to the latest World Health Organization (WHO) classification published in 2010 \[[@CR17]\], NENs are classified into the following four general categories that are mainly based on mitotic count and the Ki67 proliferation index: (1) well differentiated neuroendocrine tumor (NET) or grade 1 tumor, with a mitotic count of \<2/10 per high-power fields (HPF) and a Ki67 of ≤2%, such as a typical carcinoids; (2) intermediate differentiated NET or grade 2 tumor, with a mitotic count of between 2 and 20/10 HPF and a Ki67 of 3% to 20%, such as an atypical carcinoids; (3) poorly differentiated neuroendocrine carcinoma (NEC) or grade 3 tumor, with a mitotic count of \>20/10 HPF and a Ki67 of \>20%, which includes small-cell and large-cell NECs; and (4) mixed adenoneuroendocrine carcinoma (MANEC), histologically exhibiting concomitant adenocarcinoma (or other components) and NEC concomitantly. Primary gallbladder small-cell NEC (GB-SCNEC) is particularly rare, with only 74 cases described until 2011 \[[@CR18]\]. Large-cell neuroendocrine carcinoma of the gallbladder (GB-LCNEC) is exceedingly rare and was first reported by Papotti in 2000 \[[@CR3]\]. The histological features of LCNEC are as follows: (1) positivity for neuroendocrine markers, among which chromogranin A and synaptophysin are the most commonly identified; (2) a mitotic count exceeding 20/10 HPFs or a Ki67 index of over 20%; and (3) a specific NET pattern of an organoid structure, rosette formation, palisading, and trabecular arrangement, as well as prominent nuclei that are over three times the diameter of a lymphocyte. Although more than ten cases of GB-LCNEC have been reported in the English literature to date (Table [1](#Tab1){ref-type="table"}), there is a paucity of data on this tumor type.

We reviewed a series of 17 GB-LCNECs, including 16 previously reported cases and our present case. This series of GB-LCNECs included reports of 6 (35%) pure LCNECs and 11 (65%) LCNECs combined with other histological components, including 9 concomitant with adeno-, one with adenosquamous-, and one with mucinous carcinoma. Patients with mixed histological components were classified as having MANEC according to the WHO 2010 classification \[[@CR17]\]. Only one tumor was found to be a functional ACTH-producing tumor in this series.

Enterochromaffin cells, the precursor cells of NENs, are distributed throughout the gastrointestinal tract, bronchus, endocrine glands, and skin. These are also common sites of NEN. The gallbladder mucosa in the fundus and body is devoid of neuroendocrine cells, which may appear after intestinal metaplasia due to chronic inflammation. This fact explains why NENs rarely occur in the gallbladder. Virtually all published reports on gallbladder NENs describe coexisting gallstones and chronic cholecystitis \[[@CR19]\]. Our patient presented non-specific vague abdominal pain in the right upper quadrant, which is a typical symptom of cholelithasis and should be considered a pathogenic basis of NEC.

Similar to most previously reported cases of NEC, the clinical symptoms and radiological findings of our patient were nonspecific. According to the descriptions of the series of 17 GB-LCNECs, abdominal pain (8/17, 47%) was the most common symptom. Other symptoms, including fever, jaundice, and weight loss, were also nonspecific. SCNEC and LCNEC were confirmed to be genetically similar and distinct from well-differentiated NETs \[[@CR20]\]. LCNEC was thought to exhibit similar aggressive behavior and early metastasis compared with SCNEC \[[@CR4]\]. Among the 17 GB-LCNECs described, nine (53%) were diagnosed with direct hepatic invasion, and eight (47%) were identified with metastasis in the lymph nodes, liver, or bone. Fortunately, our case showed no signs of liver invasion or distant metastasis, which may have been attributed to early detection.

Surgical resection, which has been determined to improve the prognosis of patients with NEC \[[@CR21]\], is considered to be the main treatment for gallbladder NECs. The prognosis is very poor for patients with unresectable masses \[[@CR22]\], although multimodal treatments, including chemotherapy and radiation therapy, have achieved good responses in some reports \[[@CR7]\]. Follow-up results were reported for 13 of the 17. Among them, seven (54%) died of the disease in a median time of 14 months, while the other six patients exhibited disease-free survival (DFS) after 12 to 36 months of follow-up. Four surviving patients had some similar characteristics, such as small tumor size and no liver invasion or metastasis, and they had undergone radical surgery. The other two successful treatments for patients with liver invasion or lymph node metastasis mainly rely on extended surgery with hepatectomy and lymph node dissection. The presence of the adenocarcinoma phenotype is thought to indicate poor prognosis \[[@CR2]\]. However, we could not make a similar conclusion according to this series of the 17 GB-LCNECs.

Conclusions {#Sec4}
===========

LCNEC of the gall bladder is extremely rare and is usually present along with other carcinoma types, such as adenocarcinoma, as determined histologically. The patient prognosis is poor overall, but early detection with complete resection may result in a relatively good prognosis.

Consent {#Sec5}
=======

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the editor of this journal.
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